Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H300
UPID:
PARL_HUMAN
Alternative names:
Mitochondrial intramembrane cleaving protease PARL
Alternative UPACC:
Q9H300; Q96CQ4; Q9BTJ6; Q9P1E3
Background:
The Presenilin-associated rhomboid-like protein, mitochondrial (PARL), plays a pivotal role in apoptosis control and mitochondrial integrity. It is essential for the proteolytic processing of various mitochondrial proteins, including OPA1, PINK1, PGAM5, CLPB, DIABLO/SMAC, STARD7, and TTC19. These activities are crucial for maintaining mitochondrial function and cellular health.
Therapeutic significance:
Understanding the role of Presenilin-associated rhomboid-like protein, mitochondrial could open doors to potential therapeutic strategies.